CBMP Registry: 5,000 UK Patients Now on Medical Cannabis
The UK Medical Cannabis Registry has reached a milestone of 5,000 active patient records, providing an unprecedented dataset for understanding real-world outcomes of cannabis-based treatments.
The UK Medical Cannabis Registry, operated in partnership with several NHS bodies and independent research institutions, has announced it has surpassed 5,000 active patient records. The milestone represents a significant leap from the 3,200 records reported just 18 months ago and reflects the rapid growth of legal medical cannabis prescribing across the UK.
Registry Composition
The 5,000 registered patients represent a broad demographic and diagnostic spread. Chronic pain remains the most common primary indication, accounting for approximately 40% of registrations, followed by anxiety disorders, sleep disturbances, and neurological conditions including epilepsy and multiple sclerosis.
Emerging Outcome Patterns
- 74% of chronic pain patients reported a clinically meaningful reduction in pain scores after six months
- 68% of patients with anxiety-related conditions reported improved daily functioning
- Retention rates at 12 months stand at 71%, suggesting sustained therapeutic benefit for the majority
- Concurrent opioid use fell by an average of 42% among patients who were on opioids at baseline
Research Value
The registry dataset is now large enough to support meaningful subgroup analyses and has attracted interest from academic institutions across the UK. Three peer-reviewed publications drawing on registry data are currently in preparation.
"Reaching 5,000 patients is not just a numerical milestone. It means we now have the statistical power to answer questions about treatment response in specific patient populations that were previously unanswerable."
The registry is open to all clinics prescribing licensed CBMPs in the UK. Participation is voluntary but strongly encouraged by professional bodies including the Faculty of Pain Medicine.
